Donaldson, Scott H.

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Heijerman, H. G. M., McKone, E. F., Downey, D. G., Van Braeckel, E., Rowe, S. M., Tullis, E., Mall, M. A., Welter, J. J., Ramsey, B. W., McKee, C. M., et al. (2019) · The Lancet

Cystic Fibrosis Research AdvancesPharmacogenetics and Drug Metabolism

Cited by 1,414

Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic Fibrosis

Rowe, S. M., Heltshe, S. L., Gonska, T., Donaldson, S. H., Borowitz, D., Gelfond, D., Sagel, S. D., Khan, U., Mayer-Hamblett, N., Van Dalfsen, J. M., et al. (2014) · American Journal of Respiratory and Critical Care Medicine

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 492

Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study

Flume, P. A., Biner, R. F., Downey, D. G., Brown, C., Jain, M., Fischer, R., De Boeck, K., Sawicki, G. S., Chang, P., Paz-Diaz, H., et al. (2021) · The Lancet Respiratory Medicine

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 52